Because both the C3b deposition (extravascular hemolysis) and the MAC formation (intravascular hemolysis) are key disease characteristics in PNH, the lead molecules should ideally undergo evaluation using a comprehensive set of bioassays, rather than relying solely on the hemolysis assay during drug development. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.